|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
146426-40-6
|
|
gptkbp:clinicalTrialPhase
|
Phase II
|
|
gptkbp:color
|
yellow
|
|
gptkbp:developedBy
|
anticancer agent
|
|
gptkbp:discoveredBy
|
gptkb:Hoechst_Marion_Roussel
|
|
gptkbp:hasInChIKey
|
QBUVFDKTZJNUPP-ZDUSSCGKSA-N
|
|
gptkbp:hasMolecularFormula
|
C21H20ClNO5
|
|
gptkbp:hasSMILES
|
CN1CCC[C@H]1C2=CC(=O)C3=C(O2)C=C(C=C3O)C4=CC=CC=C4Cl
|
|
gptkbp:hasUNII
|
8N3DW7272P
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
flavopiridol
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isApprovedForUse
|
not FDA approved
|
|
gptkbp:isCytotoxic
|
true
|
|
gptkbp:isOralBioavailable
|
low
|
|
gptkbp:isSynthetic
|
true
|
|
gptkbp:IUPACName
|
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
|
|
gptkbp:mechanismOfAction
|
cyclin-dependent kinase inhibitor
|
|
gptkbp:meltingPoint
|
>200°C
|
|
gptkbp:molecularWeight
|
401.84 g/mol
|
|
gptkbp:origin
|
synthetic derivative of rohitukine
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL297
DB01205
5287969
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
neutropenia
|
|
gptkbp:synonym
|
HMR 1275
L86-8275
NSC 649890
alvocidib
|
|
gptkbp:target
|
gptkb:CDK9
gptkb:CDK2
gptkb:CDK4
gptkb:CDK6
gptkb:CDK1
|
|
gptkbp:usedInTreatmentOf
|
gptkb:acute_myeloid_leukemia
chronic lymphocytic leukemia
solid tumors
|
|
gptkbp:bfsParent
|
gptkb:cdc2
|
|
gptkbp:bfsLayer
|
5
|